Table Info

Table 1.

Comparison of pre- and post-vaccination laboratory parameters within vaccine types and over time

Laboratory parameters		Vaccine type		p value
		Nimenrix (n: 229; 49.4%)	Bexsero (n: 235; 50.6%)
		Mean ± SD or Median (25P–75P)	Mean ± SD or Median (25P–75P)
WBC (10³/µL)	Before vaccination	8,030 (6,820–9,000)	8,080 (6,910–9,200)	0.565^*
	After vaccination	7,680 (6,720–8,830)	7,880 (6,590–8,920)	0.804^*
	p value	0.186^Ω	0.102^Ω
HGB (g/dL)	Before vaccination	11.1 (10.6–12.2)	11.1 (10.5–12.2)	0.530^*
	After vaccination	11.4 (10.8–12.2)	11.4 (10.8–12.2)	0.858^*
	p value	0.113^Ω	0.015^Ω
HCT (%)	Before vaccination	33.3 (31.8–35.9)	33.1 (31.2–35.3)	0.223^*
	After vaccination	34.1 (32.5–36.3)	34.0 (32.4–36.3)	0.998^*
	p value	0.058^Ω	0.001^Ω
PLT (10³/µL)	Before vaccination	316,721 ± 59,404	316,836 ± 65,539	0.984^†
	After vaccination	312,886 ± 62,948	309,030 ± 67,329	0.524^†
	p value	0.478^¶	0.186^¶
LYM (10³/µL)	Before vaccination	4.67 ± 1.38	4.70 ± 1.52	0.833^†
	After vaccination	4.52 ± 1.26	4.64 ± 1.65	0.366^†
	p value	0.156^¶	0.680^¶
Neutrophil (10³/µL)	Before vaccination	2.55 ± 1.1	2.63 ± 1.22	0.477^†
	After vaccination	2.67 ± 1.09	2.51 ± 1.04	0.122^†
	p value	0.290^¶	0.263^¶
Monocyte (10³/µL)	Before vaccination	0.96 (0.73–1.25)	0.90 (0.65–1.25)	0.298^*
	After vaccination	0.76 (0.62–1.09)	0.81 (0.63–1.25)	0.387^*
	p value	0.004^Ω	0.170^Ω
PLR	Before vaccination	69.01 (54.78–84.47)	68.46 (54.41–84.35)	0.855^*
	After vaccination	69.57 (57.12–83.53)	69.17 (53.87–86.06)	0.522^*
	p value	0.672^Ω	0.862^Ω
NLR	Before vaccination	0.55 (0.33–0.82)	0.57 (0.33–0.83)	0.801^*
	After vaccination	0.57 (0.36–0.81)	0.52 (0.34–0.74)	0.162^*
	p value	0.374^Ω	0.739^Ω
SII	Before vaccination	171.28 (107.19–245.07)	173.71 (108.16–251.85)	0.938^*
	After vaccination	178.07 (116.04–269.14)	154.93 (103.77–256.46)	0.106^*
	p value	0.403^Ω	0.405^Ω
dNLR	Before vaccination	0.48 (0.28–0.67)	0.47 (0.28–0.7)	0.893^*
	After vaccination	0.50 (0.34–0.75)	0.43 (0.29–0.73)	0.095^*
	p value	0.118^Ω	0.748^Ω
SIR-I	Before vaccination	0.48 (0.34–0.74)	0.47 (0.29–0.84)	0.761^*
	After vaccination	0.52 (0.26–0.9)	0.47 (0.23–0.9)	0.538^*
	p value	0.244^Ω	0.859^Ω
CRP (mg/L)	Before vaccination	1.25 (0.76–2.76)	1.25 (0.85–2.55)	0.955^*
	After vaccination	1.35 (0.95–2.35)	1.45 (0.95–2.61)	0.264^*
	p value	0.297^Ω	0.458^Ω

WBC: white blood cell; HGB: hemoglobin; HCT: hematocrit; PLT: platelet; LYM: lymphocyte; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; SII: systemic immune inflammation index; dNLR: derived NLR; SIR-I: (neutrophil count × monocyte count)/lymphocyte count; CRP: C-reactive protein; SD: standard deviation. ^†: Independent samples t test was used to compare the mean values. *: Mann-Whitney U test was used to compare median values. ^Ω: Wilcoxon test for to compare median differences. ^¶: Paired samples t test for to compare the mean differences

Declarations

Author contributions

OO: Conceptualization, Investigation, Resources, Writing—original draft, Writing—review & editing, Project administration. NE: Conceptualization, Investigation, Resources, Writing—original draft, Writing—review & editing. SD: Validation, Formal analysis, Investigation, Data curation, Writing—original draft, Writing—review & editing, Project administration. US: Software, Validation, Formal analysis, Data curation, Writing—original draft, Writing—review & editing, Project administration. HU: Conceptualization, Methodology, Investigation, Resources, Writing—original draft, Writing—review & editing, Visualization, Supervision, Project administration. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

The authors declare no conflict of interest.

Ethical approval

Ethical approval of this study was obtained by the Non-Interventional Ethics Committee of the Medical Faculty of Istanbul Atlas University (04.03.2024; No: E-22686390-050.99-40431). And the study was also in accordance with the Declaration of Helsinki.

Consent to participate

The informed consent was obtained from the families of all patients prior to their inclusion in the study.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Nadel S, Ninis N. Invasive Meningococcal Disease in the Vaccine Era. Front Pediatr. 2018;6:321. [DOI] [PubMed] [PMC]

Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20. [DOI] [PubMed] [PMC]

Ölüm İstatistikleri, 2017 [Internet]. Ankara: Türkiye İstatistik Kurumu; [cited 2018 Jun 7]. Available from: https://data.tuik.gov.tr/Bulten/Index?p=Olum-Istatistikleri-2017-27592

Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5:3–14. [DOI] [PubMed] [PMC]

Bagwe P, Bajaj L, Gala R, Zughaier SM, Uddin MN, D’Souza MJ. Meningococcal Vaccines: Challenges and Prospects. Vaccines (Basel). 2020;8:738. [DOI] [PubMed] [PMC]

Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–88. [DOI] [PubMed]

Di Pietro GM, Biffi G, Castellazzi ML, Tagliabue C, Pinzani R, Bosis S, et al. Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention. Int J Environ Res Public Health. 2022;19:4035. [DOI] [PubMed] [PMC]

Millar BC, Banks L, Bourke TW, Cunningham M, Dooley J, Elshibly S, et al. Meningococcal Disease Section 3: Diagnosis and Management: MeningoNI Forum. Ulster Med J. 2018;87:94–8. [PubMed] [PMC]

Runde TJ, Anjum F, Hafner JW. Bacterial Meningitis. Treasure Island (FL): StatPearls Publishing; 2025. [PubMed]

10.

Hrishi AP, Sethuraman M. Cerebrospinal Fluid (CSF) Analysis and Interpretation in Neurocritical Care for Acute Neurological Conditions. Indian J Crit Care Med. 2019;23:S115–9. [DOI] [PubMed] [PMC]

11.

Gioia S, Piazze J, Anceschi MM, Cerekja A, Alberini A, Giancotti A, et al. Mean platelet volume: association with adverse neonatal outcome. Platelets. 2007;18:284–8. [DOI] [PubMed]

12.

Kim NY, Chun DH, Kim SY, Kim NK, Baik SH, Hong JH, et al. Prognostic Value of Systemic Inflammatory Indices, NLR, PLR, and MPV, for Predicting 1-Year Survival of Patients Undergoing Cytoreductive Surgery with HIPEC. J Clin Med. 2019;8:589. [DOI] [PubMed] [PMC]

13.

Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019;2019:9213074. [DOI] [PubMed] [PMC]

14.

Mihai A, Caruntu A, Opris-Belinski D, Jurcut C, Dima A, Caruntu C, et al. The Predictive Role of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Monocytes-to-Lymphocyte Ratio (MLR) and Gammaglobulins for the Development of Cutaneous Vasculitis Lesions in Primary Sjögren’s Syndrome. J Clin Med. 2022;11:5525. [DOI] [PubMed] [PMC]

15.

Lee JS, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Medicine (Baltimore). 2018;97:e11138. [DOI] [PubMed] [PMC]

16.

Kimberlin DW, Brady MT, Jackson MA, editors. Meningococcal Infections. Red Book (2018): Report of the Committee on Infectious Diseases. 31st ed. Itasca: American Academy of Pediatrics; 2018. pp. 550–61. [DOI]

17.

Robinson JL. Update on invasive meningococcal vaccination for Canadian children and youth. Paediatr Child Health. 2018;23:e1–4. [DOI] [PubMed] [PMC]

18.

Child and Adolescent Immunization Schedule by Age [Internet]. U.S. Centers for Disease Control and Prevention; [cited 2019 Nov 12]. Available from: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html

19.

Vaccine schedules in all countries in the EU/EEA [Internet]. European Centre for Disease Prevention and Control (ECDC); c2025 [2019 Nov 12]. Available from: https://vaccine-schedule.ecdc.europa.eu/

20.

Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine. 2018;36:5470–6. [DOI] [PubMed]

21.

Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, et al. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis. 2016;22:309–11. [DOI] [PubMed] [PMC]

22.

Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30:e41–8. [DOI] [PubMed]

23.

Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39. [DOI] [PubMed] [PMC]

24.

Dull PM, McIntosh ED. Meningococcal vaccine development – from glycoconjugates against MenACWY to proteins against MenB – potential for broad protection against meningococcal disease. Vaccine. 2012;30 Suppl 2:B18–25. [DOI] [PubMed]

25.

Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child. 2012;97:993–8. [DOI] [PubMed] [PMC]

26.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, et al. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. CMAJ. 2015;187:E215–23. [DOI] [PubMed] [PMC]

27.

Stefanizzi P, Di Lorenzo A, Martinelli A, Moscara L, Stella P, Ancona D, et al. Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019–2023. Vaccine. 2023;41:7096–102. [DOI] [PubMed]

28.

Stefanizzi P, Bianchi FP, Spinelli G, Amoruso F, Ancona D, Stella P, et al. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19. Hum Vaccin Immunother. 2022;18:1–6. [DOI] [PubMed] [PMC]

29.

Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10:2005–14. [DOI] [PubMed] [PMC]

30.

Şener G, Bayrak T, Coşkun C, Bayrak A. Neutrophil Lymphocyte Ratio, Monocyte Lymphocyte Ratio, Platelet Lymphocyte Ratio in Covid-19 Patients. Clin Lab. 2022;68. [DOI] [PubMed]

31.

Parthasarathi A, Padukudru S, Arunachal S, Basavaraj CK, Krishna MT, Ganguly K, et al. The Role of Neutrophil-to-Lymphocyte Ratio in Risk Stratification and Prognostication of COVID-19: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2022;10:1233. [DOI] [PubMed] [PMC]

32.

Shusterman E, Prozan L, Ablin JN, Weiss-Meilik A, Adler A, Choshen G, et al. Neutrophil-to-lymphocyte ratio trend at admission predicts adverse outcome in hospitalized respiratory syncytial virus patients. Heliyon. 2023;9:e16482. [DOI] [PubMed] [PMC]

33.

Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, et al. Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PLoS One. 2012;7:e42860. [DOI] [PubMed] [PMC]

34.

Wang PH, Lin SY, Liou HH, Chen CC, Shu CC, Lee CY, et al. Protective Effect of BCG and Neutrophil-to-Lymphocyte Ratio on Latent Tuberculosis in End Stage Renal Disease. Infect Dis Ther. 2023;12:1907–20. [DOI] [PubMed] [PMC]

35.

Wang S, Wan Y, Zhang W. The Clinical Value of Systemic Immune Inflammation Index (SII) in Predicting the Severity of Hospitalized Children with Mycoplasma Pneumoniae Pneumonia: A Retrospective Study. Int J Gen Med. 2024;17:935–42. [DOI] [PubMed] [PMC]

36.

Okuyan O, Elgormus Y, Sayili U, Dumur S, Isık OE, Uzun H. The Effect of Virus-Specific Vaccination on Laboratory Infection Markers of Children with Acute Rotavirus-Associated Acute Gastroenteritis. Vaccines (Basel). 2023;11:580. [DOI] [PubMed] [PMC]

37.

McDade TW, Borja JB, Kuzawa CW, Perez TL, Adair LS. C-reactive protein response to influenza vaccination as a model of mild inflammatory stimulation in the Philippines. Vaccine. 2015;33:2004–8. [DOI] [PubMed] [PMC]

38.

Ferlito C, Visco V, Biselli R, Cattaruzza MS, Carreras G, Salerno G, et al. Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization. Biomedicines. 2021;10:6. [DOI] [PubMed] [PMC]